Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Drops NovoSeven Stroke Program Following Phase III Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.

You may also be interested in...



Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins

Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.

NovoSeven Wins Expanded Indication For Acquired Hemophilia

Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.

Novo Nordisk Pulls Unlucky NovoSeven Application In EU

Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel